Skip to main content

Advertisement

Log in

Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Chronic systemic inflammatory response is proposed as an underlying mechanism for development of cancer cachexia. We conducted a prospective study to examine changes in inflammatory biomarkers during the disease course and the relationship between inflammatory biomarkers and cachexia in patients with inoperable pancreatic cancer. Twenty patients, median (range) age 67.5 (35–79) years, 5 females, were followed for median 5.5 (1–12) months. Cachexia was diagnosed according to the 2011 consensus-based classification system (weight loss >5 % past six months, BMI < 20 kg/m2 and weight loss >2 %, or sarcopenia) and the modified Glasgow Prognostic score (mGPS) that combines CRP and albumin levels. Inflammatory biomarkers were measured by enzyme immunoassays. The patients had increased levels of most inflammatory biomarkers, albeit not all statistically significant, both at study entry and close to death, indicating ongoing inflammation. According to the consensus-based classification system, eleven (55 %) patients were classified as cachectic upon inclusion. They did not differ from non-cachectic patients with regard to inflammatory biomarkers or energy intake. According to the mGPS, seven (35 %) were defined as cachectic and had a higher IL-6 (p < 0.001) than the non-cachectic patients. They also had a slightly, but insignificantly longer survival than non-cachectic patients (p = 0.08). The mGPS should be considered as an additional framework for identification of cancer cachexia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. doi:10.3322/CA.2007.0010.

    Article  PubMed  Google Scholar 

  2. Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011;15(11):1917–27. doi:10.1007/s11605-011-1665-9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997;75(1):106–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26(2):146–51. doi:10.1097/MOG.0b013e3283347e77.

    Article  PubMed  Google Scholar 

  5. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi:10.1016/S1470-2045(10)70218-7.

    Article  PubMed  Google Scholar 

  6. Hopkinson JB, Wright DN, McDonald JW, Corner JL. The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage. 2006;32(4):322–31. doi:10.1016/j.jpainsymman.2006.05.012.

    Article  PubMed  Google Scholar 

  7. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. doi:10.1016/j.clnu.2008.06.013.

    Article  CAS  PubMed  Google Scholar 

  8. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40(6):685–91.

    Article  PubMed  Google Scholar 

  9. Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011;80(1):114–44. doi:10.1016/j.critrevonc.2010.10.004.

    Article  PubMed  Google Scholar 

  10. Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, et al. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung. 2012;190(3):327–32.

    Article  CAS  PubMed  Google Scholar 

  11. Roxburgh CSD, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110(6):1409–12. doi:10.1038/bjc.2014.90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Williams GR, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol Ser A Biol Sci Med Sci. 2004;59(3):M242–8. doi:10.1093/gerona/59.3.M242.

    Article  Google Scholar 

  13. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88(3):625–36. doi:10.1016/j.critrevonc.2013.07.015.

    Article  PubMed  Google Scholar 

  14. Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res. 2005;11(16):5802–8. doi:10.1158/1078-0432.CCR-05-0185.

    Article  CAS  PubMed  Google Scholar 

  15. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331–44.

    Article  CAS  PubMed  Google Scholar 

  16. Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64.

    Article  CAS  PubMed  Google Scholar 

  17. Klepstad P, Kaasa S. The importance and pitfalls of correlational science in palliative care research. Curr Opin Support Palliat Care. 2012;6(4):508–13. doi:10.1097/SPC.0b013e32835a0c70.

    Article  PubMed  Google Scholar 

  18. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. doi:10.1158/1078-0432.CCR-08-2242.

    Article  CAS  PubMed  Google Scholar 

  19. Wesseltoft-Rao N, Holven KB, Telle-Hansen VH, Narverud I, Iversen PO, Hjermstad MJ, et al. Measurements of body fat is associated with markers of inflammation, insulin resistance and lipid levels in both overweight and in lean, healthy subjects. e-SPEN Journal. 2012;7(6):e234–40. doi:10.1016/j.clnme.2012.10.002.

    Article  Google Scholar 

  20. Lillegaard IT, Andersen LF. Validation of a pre-coded food diary with energy expenditure, comparison of under-reporters v. acceptable reporters. Br J Nutr. 2005;94(6):998–1003.

    Article  CAS  PubMed  Google Scholar 

  21. Blaker B, Aarsland M. Mål og vekt for matvarer. Oslo: Landsforeningen for Kosthold & Helse; 1989. p. 6–41.

  22. Thomas B. Manual of dietetic practice. 2nd ed. Oxford: Blacwell; 1994.

    Google Scholar 

  23. van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br J Nutr. 2013;109(12):2231–9. doi:10.1017/S0007114512004527.

    Article  PubMed  Google Scholar 

  24. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56(10):968–76. doi:10.1016/S0895-4356(03)00170-7.

    Article  PubMed  Google Scholar 

  25. Seelaender M, Batista M Jr, Lira F, Silverio R, Rossi-Fanelli F. Inflammation in cancer cachexia: to resolve or not to resolve (is that the question?). Clin Nutr. 2012;31(4):562–6. doi:10.1016/j.clnu.2012.01.011.

    Article  PubMed  Google Scholar 

  26. Bilir C, Engin H, Can M, Temi Y, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol. 2015;32(3):1–6. doi:10.1007/s12032-015-0497-y.

    Article  CAS  Google Scholar 

  27. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920–6. doi:10.1210/jc.2004-1788.

    Article  CAS  PubMed  Google Scholar 

  28. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol. 2010;8:85. doi:10.1186/1477-7819-8-85.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer. 2006;15(1):39–46. doi:10.1007/s00520-006-0091-0.

    Article  PubMed  Google Scholar 

  30. Bye A, Jordhoy MS, Skjegstad G, Ledsaak O, Iversen PO, Hjermstad MJ. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013;21(1):219–27. doi:10.1007/s00520-012-1514-8.

    Article  PubMed  Google Scholar 

  31. Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17(12):1531–41. doi:10.1007/s00520-009-0623-5.

    Article  PubMed  Google Scholar 

  32. Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, Dajani O, Ulven SM, Iversen PO, et al. Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer. Nutr Cancer. 2015;67(3):472–80.

    Article  PubMed  Google Scholar 

  33. Kyrana E, Briggs S, Dhawan A. Molecular mechanisms of cachexia in chronic disease. Expert Rev Endocrinol Metab. 2012;7(1):73–90. doi:10.1586/eem.11.87.

    Article  CAS  Google Scholar 

  34. Gordon JN, Green SR, Goggin PM. Cancer cachexia. Q J Med. 2005;98:779–88. doi:10.1093/qjmed/hci127.

    Article  CAS  Google Scholar 

  35. Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13(4):371–80. doi:10.1016/S1499-3872(14)60259-9.

    Article  PubMed  Google Scholar 

  36. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Cancer. 2004;101(12):2727–36. doi:10.1002/cncr.20672.

    Article  CAS  PubMed  Google Scholar 

  37. Scheede-Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr. 2012;31(1):85–8. doi:10.1016/j.clnu.2011.07.010.

    Article  CAS  PubMed  Google Scholar 

  38. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20(5):625–33. doi:10.2307/40272028.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106(4):966–73. doi:10.1002/cncr.21690.

    Article  CAS  PubMed  Google Scholar 

  40. Creutzberg EC, Wouters EFM, Vanderhoven-Augustin IML, Dentener MA, Schols AMWJ. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4):1239–45. doi:10.1164/ajrccm.162.4.9912016.

    Article  CAS  PubMed  Google Scholar 

  41. Li M-D. Leptin and beyond: an odyssey to the central control of body weight. Yale J Biol Med. 2011;84(1):1–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Schautz B, Later W, Heller M, Peters A, Müller MJ, Bosy-Westphal A. Impact of age on leptin and adiponectin independent of adiposity. Br J Nutr. 2012;108(02):363–70. doi:10.1017/S0007114511005605.

    Article  CAS  PubMed  Google Scholar 

  43. Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291(3):R674–R83. doi:10.1152/ajpregu.00104.2006.

    Article  CAS  PubMed  Google Scholar 

  44. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103(10):2189–98. doi:10.1002/cncr.21013.

    Article  PubMed  Google Scholar 

  45. Hall DT, Ma JF, Di Marco S, Gallouzi I-E. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. Aging (Albany NY). 2011;3(8):702–15.

    Article  Google Scholar 

  46. Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, et al. Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology. 2011;81(2):113–8. doi:10.1159/000331685.

    Article  CAS  PubMed  Google Scholar 

  47. Thoresen L, Fjeldstad I, Krogstad K, Kaasa S, Falkmer UG. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med. 2002;16(1):33–42.

    Article  PubMed  Google Scholar 

  48. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. doi:10.1016/S0140-6736(04)15841-8.

    Article  CAS  PubMed  Google Scholar 

  49. Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH. Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer. 2006;14(11):1126–33. doi:10.1007/s00520-006-0067-0.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The entire data collection was carried out at the Departments of Surgery, Oncology and Palliative Care at Oslo University Hospital. Appreciation is expressed to the staff of the study and to patients who participated.

Funding

This study was funded by Oslo and Akershus University College of Applied Sciences and Hole’s trust fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Asta Bye.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bye, A., Wesseltoft-Rao, N., Iversen, P.O. et al. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med Oncol 33, 54 (2016). https://doi.org/10.1007/s12032-016-0768-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0768-2

Keywords

Navigation